Company news

Orthocell Ltd news in 2026

Orthocell Ltd's news releases, calls and decks from 2026, newest first.

View company

Marine Biomedical Achieves FDA Clearance

November 2, 2026

Marine Biomedical Achieves FDA Clearance

November 2, 2026

Strongest U.S. Remplir Sales Month Since Launch

November 1, 2026

Strongest U.S. Remplir Sales Month Since Launch

November 1, 2026

Q1 FY27 OCC Investor Presentation

October 21, 2026

Q1 FY27 OCC Investor Presentation

October 21, 2026

Quarterly Activity Report & Appendix 4C

October 21, 2026

Quarterly Activity Report & Appendix 4C

October 21, 2026

Remplir Shows Excellent Early Prostatectomy Results

October 12, 2026

Orthocell Achieves First Remplir Sales in Thailand

September 20, 2026

Q4 FY26 ASX Investor Presentation

July 13, 2026

Orthocell Appoints Thailand Distributor for Remplir

July 2, 2026

Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine

June 28, 2026

First Sales of Remplir Achieved in US$75m Canadian Market

April 29, 2026

Compelling 90% Success Rate for Remplir in Real World Study

April 27, 2026

Q3 FY26 Investor Presentation

April 19, 2026

First Surgical Use of Remplir in US Department of Defense

April 16, 2026

Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network

April 16, 2026

OCC Secures Access to 221 U.S. Military Medical Centres

April 14, 2026

Remplir Used in 23 Surgeries in Ukrainian soldiers

March 17, 2026

Orthocell Appoints UK Distributor for Remplir

March 9, 2026

Appendix 4D & Half-Year Financial Report

February 23, 2026

Orthocell Receives $3.0m R&D Tax Refund

February 18, 2026

US Market and Operational Update

February 1, 2026

Quarterly Activity Report & Appendix 4C

January 18, 2026

Orthocell Posts Seventh Straight Record Revenue Quarter

January 5, 2026

Decks in 2026